文献速递乳腺癌支持与姑息治疗

MAF扩增对早期乳腺癌辅助唑来膦酸疗效的影响:AZURE试验二次分析

Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial.
PubMed 文献 · Lancet Oncol · 2017-10-13

该研究为AZURE III期试验的二次分析,评估MAF扩增能否预测早期乳腺癌辅助唑来膦酸的疗效。MAF阴性患者从唑来膦酸中获益,而MAF阳性且未绝经患者反而生存更差。

要点

  • MAF状态可预测辅助唑来膦酸的获益可能性,值得作为潜在伴随诊断进一步研究。
  • MAF阳性且未绝经患者接受唑来膦酸的无侵袭性疾病生存和总生存均更差。

核心结论

  • MAF状态可预测早期乳腺癌患者从辅助唑来膦酸治疗中获益的可能性,值得作为潜在伴随诊断进一步研究。

研究设计与样本

  • 国际、开放标签、随机对照III期AZURE试验的二次分析,纳入英国符合条件的II或III期乳腺癌患者,按1:1随机分配至标准辅助全身治疗组或联合唑来膦酸组。
  • 共1739例患者提供原发肿瘤样本,其中865例(50%)有两个可评估 cores(对照组445例,唑来膦酸组420例)。
  • MAF扩增通过荧光原位杂交集中检测,采用意向治疗的多变量分析评估疾病结局。

临床怎么用

  • MAF状态可能用于筛选可能从辅助唑来膦酸治疗中获益的早期乳腺癌患者,尤其MAF阴性者。
  • MAF阳性且未绝经患者接受辅助唑来膦酸可能生存更差,需谨慎评估。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adjuvant use of bisphosphonates can reduce the incidence of bone metastases in early breast cancer. Recurrence and survival seem to be improved only in postmenopausal patients, but the underlying mechanisms remain unclear. We investigated whether MAF amplification (a biomarker for bone metastasis) in primary tumours could predict the treatment outcomes of adjuvant zoledronic acid. METHODS: The study population included patients enrolled in the international, open-label, randomised, controlled, phase 3 AZURE trial at eligible UK sites who had stage II or III breast cancer and who gave consent for use of their primary tumour samples. Patients were randomly assigned (1:1) to receive standard adjuvant systemic therapy alone (control group) or with zoledronic acid every 3-4 weeks for six doses, then every 3-6 months until the end of 5 years. Minimisation took into account the number of involved axillary lymph nodes, clinical tumour stage, oestrogen-receptor status, type and timing of systemic therapy, menopausal status, statin use, and treating centre. The primary endpoint was disease-free survival; the secondary endpoint, invasive-disease-free survival, was the primary disease endpoint for the analysis in this report. MAF amplification was assessed by fluorescence in-situ hybridisation of two cores of breast tumour tissue in a microarray, done in a central laboratory by technicians unaware of treatment assignment. We used multivariate analyses to assess disease outcomes by intention to treat. We also assessed interactions between MAF-positive status and menopausal status on efficacy of zoledronic acid. The AZURE trial is registered with the International Standard Randomised Controlled Trial Registry, number ISRCTN79831382. FINDINGS: 1739 AZURE patients contributed primary tumour samples, of whom 865 (50%) had two assessable cores (445 in the control groups and 420 in the zoledronic acid group). 184 (21%) tumours were MAF positive (85 in the control groups and 99 in the zoledronic acid group) and the remaining tumours were MAF negative. At a median follow-up of 84·6 months (IQR 72·0-95·8), MAF status was not prognostic for invasive-disease-free survival in the control group (MAF-positive vs MAF-negative: hazard ratio [HR] 0·92, 95% CI 0·59-1·41), but was in the zoledronic acid group (0·52, 0·36-0·75). In patients with MAF-negative tumours, zoledronic acid was associated with higher invasive-disease-free survival than was control treatment (HR 0·74, 95% CI 0·56-0·98), but not in patients who had MAF-positive tumours. Additionally, among 121 patients not postmenopausal at randomisation with MAF-positive tumours, zoledronic acid was associated with lower invasive-disease-free survival (HR 2·47, 95% CI 1·23-4·97) and overall survival (2·27, 95% CI 1·04-4·93) than control treatment. INTERPRETATION: MAF status can predict likelihood of benefit from adjuvant zoledronic acid and merits further investigation as a potential companion diagnostic. FUNDING: Novartis Global and Inbiomotion.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Coleman R, Hall A, Albanell J, et al. Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial. Lancet Oncol. 2017. PMID: 29037984. doi:10.1016/S1470-2045(17)30603-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。